Format

Send to

Choose Destination
Eur J Clin Nutr. 2013 Feb;67(2):226-7. doi: 10.1038/ejcn.2012.191. Epub 2012 Nov 28.

β-glucans reduce LDL cholesterol in patients with myasthenia gravis.

Author information

1
Department of Clinical Neurophysiology, Institute of Neuroscience, Uppsala University, Uppsala, Sweden.

Abstract

We aimed at evaluating whether β-glucans could improve low-density lipoprotein (LDL) cholesterol levels and/or glycemic control in patients with myasthenia gravis (MG), in whom statins usually have muscle-related side effects. Fifty-nine MG patients participated in the study and received a daily dietary supplement of 3 g of β-glucans during 8 weeks. Body mass index (BMI) and blood sample analysis of lipid and glucose status were performed before and after 8 weeks intake of β-glucans. In the 52 patients who completed the study, there was a significant reduction in total cholesterol, LDL, ApoA1 and ApoB (all P<0.003). However, glycemic control and BMI were unaltered. The present study indicates that 8 weeks daily intake of 3 g of β-glucans significantly reduces total cholesterol, LDL, ApoA1 and ApoB in MG patients. β-glucans may therefore be of value in improving lipid status in MG patients, without the muscle-related side effects accompanied by statins.

PMID:
23187951
DOI:
10.1038/ejcn.2012.191
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center